Advaxis Inc. (NASDAQ:ADXS) shares were up 26.6% on Tuesday . The company traded as high as $11.25 and last traded at $10.72, with a volume of 4,712,068 shares trading hands. The stock had previously closed at $8.47.

A number of research analysts have weighed in on ADXS shares. Jefferies Group restated a “buy” rating on shares of Advaxis in a research note on Friday, June 10th. FBR & Co restated an “outperform” rating and issued a $34.00 price target on shares of Advaxis in a research note on Thursday, July 7th. HC Wainwright restated a “buy” rating on shares of Advaxis in a research note on Thursday, April 21st. Finally, Barclays PLC raised their price target on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday. Six research analysts have rated the stock with a buy rating, Advaxis presently has a consensus rating of “Buy” and an average target price of $25.80.

The company has a 50-day moving average of $8.41 and a 200 day moving average of $8.05. The firm’s market capitalization is $470.20 million.

In related news, Director Thomas J. Mckearn sold 4,100 shares of the stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total value of $30,545.00. Following the sale, the director now owns 82,120 shares in the company, valued at $611,794. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.